News
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir® Has Entered Final Portion of FDA Phase II Testing Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual…
SyneuRx Announces Closing of Public Offering Press Release Jun 23, 2021 Taipei, Taiwan, June 23, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE:6575) today announced the closing of its public offering…
Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial Press Release Jun 08, 2021 Taipei, Taiwan, June 8, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE: 6575), announced today that an IND application for…
SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan Press Release Jun 03, 2021 Taipei, Taiwan, June 3rd, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE: 6575), announced today that an IND application for SNB011, using its…
SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19 Press Release Apr 27, 2021 Taipei, Taiwan, April 27, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE:6575), announced today that a kick-off meeting…
US FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms Press Release Mar 26, 2021 On March 26, 2021, SyneuRx announced…
TFDA Approves SyneuRx's Schizophrenia Trials in Taiwan as part of its Global Schizophrenia Trials Press Release Mar 08, 2021 On March 8th, 2021, SyneuRx announced that the Taiwan FDA has…
Ω-NaBen, the Ultimate and Supreme Sodium Benzoate Press Release Jun 08, 2021 SyneuRx (TT6575) presents an important progress report in the “2021 Joint Spring Congress & Non-invasive Brain Stimulation Workshop”…
US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19 Press Release Feb 04, 2021 SyneuRx announced today that…
SyneuRx’s SNS Patent Applications Have Been Granted in Taiwan and in the US. Press Release Sep 10, 2021 Taipei, September 10, 2018--SyneuRx announced today that its SNS patent applications, titled…
